MX2009006202A - Composiciones y metodos para el tratamiento de neoplasma. - Google Patents

Composiciones y metodos para el tratamiento de neoplasma.

Info

Publication number
MX2009006202A
MX2009006202A MX2009006202A MX2009006202A MX2009006202A MX 2009006202 A MX2009006202 A MX 2009006202A MX 2009006202 A MX2009006202 A MX 2009006202A MX 2009006202 A MX2009006202 A MX 2009006202A MX 2009006202 A MX2009006202 A MX 2009006202A
Authority
MX
Mexico
Prior art keywords
treating
compositions
methods
neoplasm
neoplasms
Prior art date
Application number
MX2009006202A
Other languages
English (en)
Spanish (es)
Inventor
Robert D Mass
Gregory D Plowman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2009006202A publication Critical patent/MX2009006202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009006202A 2006-12-11 2007-05-04 Composiciones y metodos para el tratamiento de neoplasma. MX2009006202A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87446006P 2006-12-11 2006-12-11
PCT/US2007/068300 WO2008073509A2 (en) 2006-12-11 2007-05-04 Compositions and methods for treating a neoplasm

Publications (1)

Publication Number Publication Date
MX2009006202A true MX2009006202A (es) 2009-06-22

Family

ID=38521756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006202A MX2009006202A (es) 2006-12-11 2007-05-04 Composiciones y metodos para el tratamiento de neoplasma.

Country Status (17)

Country Link
US (1) US20100086544A1 (OSRAM)
EP (1) EP2099489B1 (OSRAM)
JP (1) JP2010512407A (OSRAM)
KR (1) KR101320198B1 (OSRAM)
CN (1) CN101547705B (OSRAM)
AU (1) AU2007333565A1 (OSRAM)
BR (1) BRPI0717688A2 (OSRAM)
CA (1) CA2670707A1 (OSRAM)
DK (1) DK2099489T3 (OSRAM)
IL (1) IL198852A (OSRAM)
MX (1) MX2009006202A (OSRAM)
NZ (1) NZ577058A (OSRAM)
RU (1) RU2482877C2 (OSRAM)
SG (1) SG177891A1 (OSRAM)
SI (1) SI2099489T1 (OSRAM)
WO (1) WO2008073509A2 (OSRAM)
ZA (1) ZA200903489B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018260B1 (ru) * 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
PL2488204T3 (pl) 2009-10-16 2016-10-31 Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem dll4 i środków antyhipertensyjnych
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
DK3485903T5 (da) 2011-09-23 2024-09-02 Mereo Biopharma 5 Inc Vegf/dll4-bindende midler og anvendelser deraf
AU2013232208B2 (en) * 2012-03-14 2017-04-27 Indiana University Research And Technology Corporation Compounds and methods for treating leukemia
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
JP6827415B2 (ja) 2014-10-31 2021-02-10 メレオ バイオファーマ ５ インコーポレイテッド 疾患の処置のための併用療法
DK3330259T3 (da) 2015-07-27 2020-08-10 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne
DK3328843T3 (da) 2015-07-27 2023-01-09 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazolsulfonamidderivat-forbindelser som histon- deacetylase-6-inhibitor, og den farmaceutske sammensætning
AU2016299486B2 (en) 2015-07-27 2019-08-01 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
EP3331864B1 (en) 2015-08-04 2021-11-03 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
MX384527B (es) 2015-10-12 2025-03-14 Chong Kun Dang Pharmaceutical Corp Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
ES3009668T3 (en) 2018-01-26 2025-03-31 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
TWI748491B (zh) 2019-05-31 2021-12-01 韓商鐘根堂股份有限公司 作為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑高鄰苯二甲醯亞胺衍生化合物及包含彼之醫藥組合物
EP4065150A4 (en) 2019-11-25 2023-12-06 The Regents of the University of California LONG-ACTING VEGF INHIBITORS FOR INTRAVASCULAR NEOVASCULARIZATION

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
AU763361B2 (en) * 1998-09-25 2003-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/CDK complexes
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
US6638965B2 (en) * 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體

Also Published As

Publication number Publication date
BRPI0717688A2 (pt) 2013-01-22
CA2670707A1 (en) 2008-06-19
JP2010512407A (ja) 2010-04-22
RU2009126588A (ru) 2011-01-20
NZ577058A (en) 2012-04-27
DK2099489T3 (da) 2014-08-18
WO2008073509A3 (en) 2009-01-08
RU2482877C2 (ru) 2013-05-27
KR20090087908A (ko) 2009-08-18
EP2099489A2 (en) 2009-09-16
SG177891A1 (en) 2012-02-28
AU2007333565A1 (en) 2008-06-19
SI2099489T1 (sl) 2014-09-30
CN101547705A (zh) 2009-09-30
CN101547705B (zh) 2013-06-12
HK1131064A1 (en) 2010-01-15
KR101320198B1 (ko) 2013-10-30
IL198852A (en) 2013-06-27
IL198852A0 (en) 2011-08-01
EP2099489B1 (en) 2014-05-21
WO2008073509A2 (en) 2008-06-19
ZA200903489B (en) 2010-08-25
US20100086544A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
MX2009006202A (es) Composiciones y metodos para el tratamiento de neoplasma.
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
MX354099B (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW200744568A (en) Epinephrine dosing regimens
MY173616A (en) Compositions and methods for lowering triglycerides
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
IL226717A0 (en) Antibodies@ofpeople@of@@@beta@and their use
MY151191A (en) Novel antibodies
IN2012DN00572A (OSRAM)
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
EP2331093A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATMENT PREVENTING DISEASES
GB2466912A (en) Compositions and methods for treating lysosomal disorders
EA201070059A1 (ru) Композиции, содержащие ингибиторы триптофангидроксилазы
TW200727920A (en) New regimens for oral monophasic contraceptives
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
TW200700071A (en) Novel use
ZA200807281B (en) CCR5 antagonists useful for treating HIV
MX2013008559A (es) Derivados de leptina.
TN2010000463A1 (en) Compositions and methods for preparing and using same
MX2010003373A (es) Moduladores de receptores muscarinicos.
EP1722782A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING OR TREATING HIV-1

Legal Events

Date Code Title Description
FG Grant or registration